Regular Screenings Can Lead to Better Results
Even if you do not have signs, screening for PAH associated with scleroderma is essential. It can help you get a diagnosis early, when the disease is still considered mild*
Regular screening and early diagnosis of PAH may help people with PAH associated with scleroderma have better clinical results, such as reduced symptoms and less severe disease†
Research has shown that patients with scleroderma who were proactively screened for PAH had higher survival rates than people diagnosed during regular clinical practice†
Because PAH can begin before you notice it, yearly screening is
important to help your rheumatologist catch it early.
Take Charge of Your Health
If you have scleroderma, experts recommend yearly screening for PAH.‡
See moreHave Questions About PAH?
See some of the most commonly asked questions about scleroderma and PAH.
Find answers*Mild disease includes early World Health Organization (WHO) Functional Class (I or II), moderately elevated mean pulmonary arterial pressure and pulmonary vascular resistance, and a preserved cardiac index.
†People from the French PAH Registry and the ItinérAIR-Sclérodermie program who were diagnosed with PAH with proactive screening included people with systemic sclerosis who entered a systematic PAH detection program and were subsequently found to have PAH with a right heart catheterization. People who were diagnosed during the routine practice group included consecutive adults with symptomatic systemic sclerosis diagnosed with PAH by right heart catheterization at the time of recruitment into the French PAH Registry.
‡Recommendations for yearly PAH screening of people with systemic sclerosis are included in the 2022 European Society of Cardiology/European Respiratory Society Guidelines.